Evidence map›Paper›PMID 35457088›Full record

ArticleInternational journal of molecular sciences2022

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy.

Elena Marchesi, Rita Cortesi, Lorenzo Preti, Paola Rimessi, Maddalena Sguizzato, Matteo Bovolenta, Daniela Perrone

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elena MarchesiDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-5402-4732
Rita CortesiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-1060-2676
Lorenzo PretiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-5912-998X
Paola RimessiUnit of Medical Genetics, S. Anna University-Hospital, 44121 Ferrara, Italy.
Maddalena SguizzatoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-2100-2043
Matteo BovolentaDepartment of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-9937-009X
Daniela PerroneDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-5189-011X
University of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our groups previously reported that conjugation at 3'-end with ursodeoxycholic acid (UDCA) significantly enhanced in vitro exon skipping properties of ASO 51 oligonucleotide targeting the human DMD exon 51. In this study, we designed a series of lipophilic conjugates of ASO 51, to explore the influence of the lipophilic moiety on exon skipping efficiency. To this end, three bile acids and two fatty acids have been derivatized and/or modified and conjugated to ASO 51 by automatized solid phase synthesis. We measured the melting temperature (

Indexed as

Muscular Dystrophy, DuchenneCell LineDystrophinExonsHumansOligonucleotidesOligonucleotides, AntisenseDystrophinOligonucleotidesOligonucleotides, Antisense2′-O-methyl-phosphorothioate (2′-OMe PS)antisense oligonucleotidebile acidconjugationDuchenne muscular dystrophyexon skippinglipophilic compoundursodeoxycholic acid (UDCA)

Identifiers

PMID35457088
PMCPMC9032562
OpenAlexW4223642342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.